Breathe Well Live Well
|
Teva's asthma candidates successful in three late-stage studies; regulatory …
Seeking Alpha Top-line results from three Phase 3 clinical trials assessing Teva Pharmaceutical Industries' (TEVA +0.4%) fluticasone propionate/salmeterol, a combination inhaled corticosteroid and long-acting beta agonist delivered via a multidose dry powder inhaler … |
View full post on asthma – Google News
|
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute …
Sacramento Bee One of these agents, R343, an inhaled SYK inhibitor, will be entering a Phase 2 clinical study later this summer in mild to moderate asthmatic patients. The other, R256, an inhaled IL13 signaling/JAK inhibitor, is potentially useful in controlling … Rigel moving asthma drug into mid-stage trial |
View full post on asthma – Google News
|
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute …
MarketWatch (press release) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire via COMTEX/ — Rigel Pharmaceuticals, Inc., (NASDAQ:RIGL) is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma. |
View full post on asthma – Google News
|
Researchers Find New Molecular Candidates For Treatment of Asthma and Allergies
Newswise (press release) The research team, led by Toshiaki Kawakami, MD, Ph.D., is also the first to clarify the role of the HRF molecule in promoting asthma and some allergies, including identifying its receptor – a major finding that answers a long-held and important … |
View full post on asthma – Google News
|
La Jolla Institute finds new molecular candidates for treatment of asthma and …
EurekAlert (press release) SAN DIEGO – (December 1, 2011) La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma. … |
View full post on asthma – Google News